Prostate Cancer Management from Early Stage to Advanced Metastatic Disease - Dr. Alan Bryce

Join us in this insightful episode of the Oncology Brothers podcast as we dive deep into the current treatment landscape of prostate cancer with Dr. Alan Bryce, Chief Clinical Officer and GU Medical Oncologist from City of Hope.

In this episode, we explore:
•⁠  ⁠The treatment paradigm for early-stage prostate cancer, including the role of active surveillance and the use of abiraterone based on the STAMPEDE trial.
•⁠  ⁠The importance of understanding risk factors and treatment options for low, intermediate, and high-risk patients.
•⁠  ⁠The implications of PET-PSMA imaging versus conventional CT modalities in staging and treatment decisions.
•⁠  ⁠The management of biochemical recurrent disease and the significance of PSA doubling time in treatment planning.
•⁠  ⁠The role of PARP inhibitors in patients with HRR mutations and the nuances of selecting appropriate therapies.
•⁠  ⁠Strategies for managing metastatic disease, including the use of Lutetium-177 (Pluvicto) and cabazitaxel.

Dr. Bryce provides a masterclass on navigating the complexities of prostate cancer treatment, emphasizing the need to balance between over-treatment in early disease and under-treatment in metastatic cases.

YouTube: https://youtu.be/Zfu-yGmH0rg

Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠  Website: https://oncbrothers.com/

If you find this episode helpful, please share it with your colleagues and leave us a review! Don't forget to check out our other episodes in the GU treatment algorithm series, including discussions on renal cell carcinoma and bladder cancer.